SCHEMBL22985916

SCHEMBL22985916

C=C(/C=C(\C=C/CNc1nc(Nc2ccccc2S(=O)(=O)C(C)C)c2c(Cl)c[nH]c2n1)C(=O)N1CCC(N2CCOCC2)CC1)OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 16/20 0.48
▸ PTK2 Q05397 2/20 0.42
▸ TTK P33981 2/20 0.41
▸ LRRK2 Q5S007 3/20 0.40
▸ INSR P06213 2/20 0.40
▸ MET P08581 2/20 0.40
▸ BMPR1B O00238 1/20 0.40
▸ PLK4 O00444 1/20 0.40
▸ STK25 O00506 1/20 0.40
▸ RIOK3 O14730 1/20 0.40
▸ CHEK1 O14757 1/20 0.40
▸ CASK O14936 1/20 0.40
▸ AURKA O14965 1/20 0.40
▸ GAK O14976 1/20 0.40
▸ DCLK1 O15075 1/20 0.40
▸ MUSK O15146 1/20 0.40
▸ EPHB6 O15197 1/20 0.40
▸ PDPK1 O15530 1/20 0.40
▸ MAP3K13 O43283 1/20 0.40
▸ DAPK3 O43293 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18018792 0.79 LRRK2 (0.65) ALKPTK2TTKLRRK2INSR
SCHEMBL22985863 0.75 ALK (0.63) ALKPTK2TTKLRRK2INSR
SCHEMBL18018791 0.73 LRRK2 (0.72) ALKTTKLRRK2MAP3K9MKNK2
SCHEMBL18018790 0.69 ALK (0.79) ALKPTK2TTKLRRK2INSR
SCHEMBL18018962 0.67 LRRK2 (0.75) TTKLRRK2CLK1CLK2CLK3
SCHEMBL22985864 0.67 LRRK2 (0.66) TTKLRRK2CLK1CLK2CLK3
SCHEMBL22985899 0.66 LRRK2 (0.76) TTKLRRK2CLK1CLK2CLK3
SCHEMBL30978788 0.66 CDK7 (0.72) ALKPTK2TTKLRRK2INSR
SCHEMBL18018966 0.66 LRRK2 (0.74) TTKLRRK2CLK1CLK2CLK3
SCHEMBL22658522 0.65 LRRK2 (0.50) PTK2TTKLRRK2CLK1CLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3778604-A1 LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME Dana Farber Cancer Institute, Inc. (US) 2021-02-17 — — EP disclosed
EP-3778605-A2 LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME Dana Farber Cancer Institute, Inc. (US) 2021-02-17 — — EP disclosed
Send feedback